BeOne Medicines (NASDAQ:ONC) SVP Chan Henry Lee Sells 664 Shares of Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 664 shares of the business’s stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $302.46, for a total transaction of $200,833.44. Following the transaction, the senior vice president owned 202 shares in the company, valued at approximately $61,096.92. The trade was a 76.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Chan Henry Lee also recently made the following trade(s):

• On Tuesday, June 16th, Chan Henry Lee sold 590 shares of BeOne Medicines stock. The shares were sold at an average price of $265.98, for a total transaction of $156,928.20.
• On Thursday, June 11th, Chan Henry Lee sold 428 shares of BeOne Medicines stock. The shares were sold at an average price of $257.63, for a total transaction of $110,265.64.
• On Monday, June 8th, Chan Henry Lee sold 871 shares of BeOne Medicines stock. The stock was sold at an average price of $270.42, for a total transaction of $235,535.82.
• On Wednesday, May 13th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The shares were sold at an average price of $310.72, for a total transaction of $103,159.04.

BeOne Medicines Stock Performance

NASDAQ:ONC traded down $4.13 during mid-day trading on Friday, hitting $298.70. The stock had a trading volume of 254,502 shares, compared to its average volume of 270,452. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $249.00 and a twelve month high of $385.22. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64. The stock has a market cap of $32.77 billion, a price-to-earnings ratio of 66.82 and a beta of 0.49. The company’s 50 day simple moving average is $289.89 and its 200 day simple moving average is $309.03.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The firm had revenue of $1.51 billion for the quarter. On average, equities research analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 5.86 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ONC has been the subject of several research reports. Morgan Stanley reaffirmed an “overweight” rating and set a $395.00 price target on shares of BeOne Medicines in a report on Thursday, May 7th. Zacks Research cut shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 3rd. Wells Fargo & Company initiated coverage on shares of BeOne Medicines in a report on Monday, May 4th. They set an “overweight” rating and a $400.00 target price for the company. Barclays increased their price target on shares of BeOne Medicines from $405.00 to $409.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Finally, Truist Financial boosted their price objective on BeOne Medicines from $413.00 to $416.00 and gave the stock a “buy” rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $391.38.

Institutional Investors Weigh In On BeOne Medicines

A number of institutional investors have recently modified their holdings of the business. Generali Investments Management Co LLC bought a new position in BeOne Medicines during the second quarter worth about $2,280,000. Charles Schwab Trust Co acquired a new position in shares of BeOne Medicines during the 2nd quarter worth approximately $855,000. Steadtrust LLC increased its holdings in shares of BeOne Medicines by 3.7% during the second quarter. Steadtrust LLC now owns 1,400 shares of the company’s stock worth $399,000 after purchasing an additional 50 shares during the period. Empowered Funds LLC acquired a new stake in shares of BeOne Medicines in the first quarter valued at approximately $201,000. Finally, Bank of America Corp DE boosted its stake in shares of BeOne Medicines by 7.0% in the first quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock valued at $120,354,000 after buying an additional 26,441 shares during the period. Institutional investors own 48.55% of the company’s stock.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.